Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab
Carl C Awh, Giulio Barteselli, Sneha Makadia, Robert T Chang, Jay M Stewart, Mark R Wieland, Raymond Brassard, Natalia F Callaway, Shamika Gune, Pam Heatherton, Varun Malhotra, Jeffrey R Willis, Dante J Pieramici, Carl C Awh, Giulio Barteselli, Sneha Makadia, Robert T Chang, Jay M Stewart, Mark R Wieland, Raymond Brassard, Natalia F Callaway, Shamika Gune, Pam Heatherton, Varun Malhotra, Jeffrey R Willis, Dante J Pieramici
Abstract
Purpose: To provide strategies for the management of key ocular adverse events (AEs) that may be encountered with the Port Delivery System with ranibizumab (PDS) in practice and provide recommendations that may mitigate such AEs based on clinical trial experiences and considerations from experts in the field.
Design: Safety evaluation based on the phase 2 Ladder (NCT02510794) and phase 3 Archway (NCT03677934) trials of the PDS.
Methods: The PDS implant is a permanent, indwelling, and refillable ocular drug delivery system that requires standardized procedural steps for its insertion and refill-exchange procedures, which evolved during the PDS clinical program. We described identified AEs that may arise after implant insertion or refill-exchange procedures, including conjunctival retraction, conjunctival erosion, endophthalmitis, implant dislocation, conjunctival blebs or conjunctival filtering bleb leaks, wound leaks, hypotony, choroidal detachment, vitreous hemorrhage, rhegmatogenous retinal detachment, cataract, and septum dislodgement.
Results: Adverse events related to the PDS were well understood, were manageable by trial investigators, and did not prevent patients from achieving optimal outcomes in most cases.
Conclusions: Surgeons using the PDS should be aware of potential ocular AEs and identify them early for optimal management. As with any new surgical procedure, it is important to provide surgeons with appropriate training, ensure adherence to optimal surgical techniques, and continually refine the procedure to mitigate complications and improve outcomes.
Keywords: Adverse events; Age-related macular degeneration; Ocular implant; Port Delivery System with ranibizumab; Vascular endothelial growth factor.
Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Source: PubMed